Enterotoxigenic B. fragilis Acquisition in Disease Susceptibility

产肠毒素脆弱拟杆菌的获得与疾病易感性

基本信息

  • 批准号:
    10468700
  • 负责人:
  • 金额:
    $ 39.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-13 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Inflammatory bowel disease (IBD) and colonic malignancy are heterogeneous disease states that result from a complex interplay of host genetic and environmental factors. It is becoming increasingly clear that early events in development of the colonic microbiota influence host immunity, nutrition, and susceptibility to disease. Bacteroides fragilis comprises up to 2.5% of the human microbiota, and is often acquired within the first month of life. A subspecies of Bacteroides fragilis termed enterotoxigenic B. fragilis (ETBF) releases B. fragilis toxin (BFT), a zinc-dependent metalloprotease that causes a pro-inflammatory injury of the intestinal epithelium. ETBF has been implicated in the pathogenesis of IBD, colon tumorigenesis, acute diarrhea, and undernutrition in children. ETBF colonizes up to 20% of asymptomatic humans, suggesting that these individuals may incur an underappreciated long-term health risk from chronic carriage. We have demonstrated that competition for the B. fragilis niche within the colon is governed by strain-specific determinants including the Type VI bacterial secretion system. Further, the acquisition of protective strains of NTBF that restrict ETBF acquisition blunt the toxic effects of ETBF and thereby mitigate disease. The primary goal of this proposal is to examine neonatal acquisition of ETBF as a determinant of host susceptibility to disease. Through a comprehensive analysis of the genetic determinants of ETBF colonic niche establishment and the mechanisms by which BFT is expressed and released to act upon host cells, this study will define fundamental mechanisms that underlie ETBF-mediated disease. These studies will benefit from the use of a novel model of B. fragilis vertical transmission in which the temporal and genetic determinants of initial niche colonization by B. fragilis is examined in neonatal mice. It is anticipated that these studies will shed light on strategic opportunities for genetically informed probiotic-based approaches to modulate colonic disease through strain-specific niche competition, precluding the deleterious acquisition of ETBF that renders a host susceptible to disease.
项目总结

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Bacteroides fragilis toxin expression enables lamina propria niche acquisition in the developing mouse gut.
脆弱拟杆菌毒素的表达能够在发育中的小鼠肠道中获得固有层生态位。
  • DOI:
    10.1038/s41564-023-01559-9
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    28.3
  • 作者:
    Hill,CraigA;Casterline,BenjaminW;Valguarnera,Ezequiel;Hecht,AaronL;Shepherd,ElizabethStanley;Sonnenburg,JustinL;BubeckWardenburg,Juliane
  • 通讯作者:
    BubeckWardenburg,Juliane
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Juliane Bubeck Wardenburg其他文献

Juliane Bubeck Wardenburg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Juliane Bubeck Wardenburg', 18)}}的其他基金

ADAM10 polymorphism in susceptibility to S. aureus disease
ADAM10 多态性对金黄色葡萄球菌病的易感性
  • 批准号:
    10649082
  • 财政年份:
    2023
  • 资助金额:
    $ 39.38万
  • 项目类别:
Development of a Pre-Exposure Vaccine for Population-Level ProtectionAgainst Staphylococcus aureus Infection
开发针对人群级别的金黄色葡萄球菌感染预防暴露前疫苗
  • 批准号:
    10483136
  • 财政年份:
    2022
  • 资助金额:
    $ 39.38万
  • 项目类别:
Enterotoxigenic Bacteroides fragilis in modulation of host immunity
产肠毒素脆弱拟杆菌对宿主免疫的调节作用
  • 批准号:
    10318195
  • 财政年份:
    2021
  • 资助金额:
    $ 39.38万
  • 项目类别:
Development of human adaptive immunity to Staphylococcus aureus
人类对金黄色葡萄球菌适应性免疫的发展
  • 批准号:
    10366018
  • 财政年份:
    2021
  • 资助金额:
    $ 39.38万
  • 项目类别:
Development of human adaptive immunity to Staphylococcus aureus
人类对金黄色葡萄球菌适应性免疫的发展
  • 批准号:
    10199312
  • 财政年份:
    2021
  • 资助金额:
    $ 39.38万
  • 项目类别:
Development of human adaptive immunity to Staphylococcus aureus
人类对金黄色葡萄球菌适应性免疫的发展
  • 批准号:
    10577832
  • 财政年份:
    2021
  • 资助金额:
    $ 39.38万
  • 项目类别:
Enterotoxigenic B. fragilis Acquisition in Disease Susceptibility
产肠毒素脆弱拟杆菌的获得与疾病易感性
  • 批准号:
    10228659
  • 财政年份:
    2018
  • 资助金额:
    $ 39.38万
  • 项目类别:
Analysis of ADAM10 in infection-associated MODS
ADAM10 在感染相关 MODS 中的分析
  • 批准号:
    9379668
  • 财政年份:
    2017
  • 资助金额:
    $ 39.38万
  • 项目类别:
Pediatric Cardiovascular and Pulmonary Research Training Program
儿科心血管和肺研究培训计划
  • 批准号:
    10115783
  • 财政年份:
    2015
  • 资助金额:
    $ 39.38万
  • 项目类别:
Pediatric Cardiovascular and Pulmonary Research Training Program
儿科心血管和肺研究培训计划
  • 批准号:
    10576362
  • 财政年份:
    2015
  • 资助金额:
    $ 39.38万
  • 项目类别:

相似海外基金

NUFENOXOLE AND ANTIBIOTICS IN TREATMENT OF ACUTE DIARRHEA
纽芬诺和抗生素治疗急性腹泻
  • 批准号:
    4703610
  • 财政年份:
  • 资助金额:
    $ 39.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了